Philadelphia, November 15, 2021—The Principal Investigator Committee of the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) re-elected Mitchell D. Schnall, MD, PhD, as the Group Co-Chair, a position he has held since the founding of the Group in 2012. He represents the diagnostic imaging-based disciplines. Dr. Schnall will serve in this role from 2021 through 2031.
Dr. Schnall co-leads the organization’s governance and is a member of several scientific committees, where he provides significant influence over the Group’s explorations of emerging imaging technologies. In addition, he currently oversees two landmark imaging trials: the TMIST breast cancer screening trial and EA2185, the surveillance trial for non-cancerous pancreatic cysts. Dr. Schnall is Chairman of the Department of Radiology and the Eugene P. Pendergrass Professor of Radiology at the Perelman School of Medicine, University of Pennsylvania in Philadelphia. He is a physician at Penn Medicine within its Abdominal Imaging Services program..
As Group Co-Chair, Dr. Schnall will continue to ensure the effective integration of radiology research with medical oncology and other disciplines involved in cancer research. His scientific priorities for his new term are the science of biomarker screening, the integration of emerging radiological technologies and their relationship between screening and prevention, the evolution of a new generation of biomarkers–particularly the complex radiomic markers, new ways to look at immune response, and imaging-guided therapy. In addition, he will continue his work to expand diversity in ECOG-ACRIN by promoting women and underserved minorities. He also plans to engage physicians from diverse specialties necessary for prevention and early detection studies, using ECOG-ACRIN’s Mentoring Program and other means.
Director of Communications
Inquire and request an interview by email
About the ECOG-ACRIN Cancer Research Group
The ECOG-ACRIN Cancer Research Group is a membership-based scientific organization that designs and conducts cancer research involving adults who have or are at risk of developing cancer. ECOG-ACRIN comprises nearly 1300 member institutions in the United States and around the world. Approximately 15,000 physicians, translational scientists, and associated research professionals from the member institutions are involved in Group research across three scientific programs: Cancer Control and Outcomes, Therapeutic Studies, and Biomarker Sciences. ECOG-ACRIN is supported primarily through National Cancer Institute research grant funding but also receives funding from private sector organizations through philanthropy and collaborations. Its headquarters are in Philadelphia, Pa. Visit www.ecog-acrin.org, follow us on Twitter @eaonc, Facebook, and LinkedIn, or call 215.789.3631.